KR920700037A - 치료에 유용한 혈소판 항-응집 효과를 갖는 조성물 - Google Patents

치료에 유용한 혈소판 항-응집 효과를 갖는 조성물

Info

Publication number
KR920700037A
KR920700037A KR1019900702419A KR900702419A KR920700037A KR 920700037 A KR920700037 A KR 920700037A KR 1019900702419 A KR1019900702419 A KR 1019900702419A KR 900702419 A KR900702419 A KR 900702419A KR 920700037 A KR920700037 A KR 920700037A
Authority
KR
South Korea
Prior art keywords
treatment
taurine
acetylsalicylic acid
composition
agglomerative
Prior art date
Application number
KR1019900702419A
Other languages
English (en)
Other versions
KR0169118B1 (ko
Inventor
제슈 코바흐비아
Original Assignee
찰스 에반스 맥파르랑
나티벨르(쏘시에떼 아노님)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 찰스 에반스 맥파르랑, 나티벨르(쏘시에떼 아노님) filed Critical 찰스 에반스 맥파르랑
Publication of KR920700037A publication Critical patent/KR920700037A/ko
Application granted granted Critical
Publication of KR0169118B1 publication Critical patent/KR0169118B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

치료에 유용한 혈소판 항-응집 효과를 갖는 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 아세틸살리실산과 타우린 중량비가 1/5 내지 1/50으로 이루어진 약제학적으로 효과적인 양의 아세틸살리실산과 타우린의 조합물, 또는 그의 각각의 염들을 필요하다면 하나 또는 수개의 약학적으로 허용가능한 담체와 배합하여 이루어짐을 특징으로 하는, 혈소판 항응집 활성을 갖는 치료에 유용한 조성물.
  2. 제 1 항에 있어서, 타우린에 대한 아세틸살리실산의 중량비가 1:10 내지 1:30 사이에서 이루어짐을 특징으로 하는 조성물.
  3. 제 2 항에 있어서, 20 내지 50mg의 아세틸살리실산 및 400 내지 500mg의 타우린을 함유하는 단위 용량으로 이루어짐을 특징으로 하는 조성물.
  4. 제 1 내지 3항중 어느 한 항에 따른 조성물을 동맥 및 세동맥 혈전증 치료용 약제를 제조하는 데에 사용하는 방법.
    ※ 참고사항 : 최초 출원 내용에 의하여 공개하는 것임.
KR1019900702419A 1989-03-10 1990-03-06 치료에 유용한 혈소판 항-응집 효과를 갖는 조성물 KR0169118B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR89/03138 1989-03-10
FR8903138A FR2644061A1 (fr) 1989-03-10 1989-03-10 Composition a activite antiagregante plaquettaire utilisable en therapeutique
PCT/FR1990/000149 WO1990010447A1 (fr) 1989-03-10 1990-03-06 Composition a activite anti-agregante plaquettaire utilisable en therapeutique

Publications (2)

Publication Number Publication Date
KR920700037A true KR920700037A (ko) 1992-02-19
KR0169118B1 KR0169118B1 (ko) 1999-01-15

Family

ID=9379557

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702419A KR0169118B1 (ko) 1989-03-10 1990-03-06 치료에 유용한 혈소판 항-응집 효과를 갖는 조성물

Country Status (10)

Country Link
EP (1) EP0387140B1 (ko)
JP (1) JP2935138B2 (ko)
KR (1) KR0169118B1 (ko)
AT (1) ATE106733T1 (ko)
CA (1) CA2027593C (ko)
DE (1) DE69009538T2 (ko)
ES (1) ES2058832T3 (ko)
FR (1) FR2644061A1 (ko)
MX (1) MX174250B (ko)
WO (1) WO1990010447A1 (ko)

Also Published As

Publication number Publication date
FR2644061B1 (ko) 1994-04-22
EP0387140A1 (fr) 1990-09-12
ES2058832T3 (es) 1994-11-01
JPH03504509A (ja) 1991-10-03
JP2935138B2 (ja) 1999-08-16
KR0169118B1 (ko) 1999-01-15
CA2027593A1 (fr) 1990-09-11
DE69009538T2 (de) 1995-01-12
EP0387140B1 (fr) 1994-06-08
ATE106733T1 (de) 1994-06-15
MX174250B (es) 1994-05-02
FR2644061A1 (fr) 1990-09-14
DE69009538D1 (de) 1994-07-14
WO1990010447A1 (fr) 1990-09-20
CA2027593C (fr) 2001-01-02

Similar Documents

Publication Publication Date Title
LV10050A (lv) Farmaceitiska kompozicija ar zemam orala antikoagulanta un trombocitu inhibitora devam
DE68913132T2 (de) Hirudin und Aktivator des Plasminogens enthaltende pharmazeutische wirksame Verbindung.
KR920017655A (ko) 상처의 치료를 촉진시키기 위한 약학 조성물
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
ATE154011T1 (de) Inhibitoren der calciumaufnahme
SE9002500D0 (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
IT1212141B (it) Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
DK481388D0 (da) Calciumtilskud
KR920002151A (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
KR910009267A (ko) 우울증의 치료방법
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
KR920700037A (ko) 치료에 유용한 혈소판 항-응집 효과를 갖는 조성물
ES2058771T3 (es) Preparado combinado con efecto antitrombotico.
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
KR910018028A (ko) 15- 데히드록시-16-옥소프로스타글란딘 화합물에 의한 생화학적 치료
IT1224250B (it) Associzione del depiprazolo con la morfina
DE69112747T2 (de) Inhibitoren der Calciumaufnahme.
KR910007524A (ko) 관상동맥 부전증 치료를 위한 약제 제조에 있어 카보티오아미드 1-옥사이드의 이용
KR940011006A (ko) 황금추출물을 유효성분으로 하는 치주질환예방 및 치료제 조성물
KR890001567A (ko) 디플루니살 및 트로메타민-함유 조성물
KR890001549A (ko) 위염 치료제
KR890000089A (ko) 신장 질환 치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee